HUTCHMED (HCM) 6-KHUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

​

Exhibit 99.2

​

​

Total Voting Rights

​
​
Hong Kong, Shanghai & Florham Park, NJ — Friday, November 29, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) hereby notifies the market that as at November 29, 2024, the issued share capital of HUTCHMED consisted of 871,601,095 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

​

The above figure of 871,601,095 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

​

For illustrative purposes only, the 871,601,095 ordinary shares would be equivalent to 871,601,095 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,320,219 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

​

About HUTCHMED

​

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan.  For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

​

Contacts

​

​